LLY
Eli Lilly and Company
LLY has the edge over TEVA overall, supported by stronger fundamentals and stronger modeled upside.
TEVA
Teva Pharmaceutical Industries Limited
TEVA's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TEVA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
TEVA's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over TEVA in the historical PE scenario, which offers more potential upside but is not a forecast.
TEVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $6.18 | -86% |
| Forward | 15x | $43.65 | — |
| Fair | 26x | $11.34 | -74% |
| Expensive | 59x | $25.80 | -41% |
| Current | 99x | $43.65 | — |
Historical ranges are pointers, not guarantees.
TEVA's PE is in its expensive range at 99x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over TEVA on the outlook, with more favorable revenue expectations.
TEVA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect TEVA's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TEVA on earnings, with more consistent year-over-year improvement.
TEVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +542% |
| Q3 2026 | $0.44 | -27% |
| Q2 2026 | $0.61 | +$0.77 |
| Q1 2026 | $1.34 | +$2.49 |
| Q4 2025 | $1.21 | +$2.66 |
| Q3 2025 | $0.60 | +$1.44 |
| Q2 2025 | -$0.16 | +$0.22 |
| Q1 2025 | -$1.15 | -$0.75 |
| Q4 2024 | -$1.45 | -$0.99 |
TEVA earned $0.44 per share over the past year, down 27% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TEVA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TEVA on profitability, with a higher operating margin.
TEVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.4B | -1.9% |
| Q2 2026 | $4.1B | -0.8% |
| Q1 2026 | $4B | +2.3% |
| Q4 2025 | $1.5B | -65% |
| Q3 2025 | $4.5B | +3.4% |
| Q2 2025 | $4.2B | +0.3% |
| Q1 2025 | $3.9B | +1.9% |
| Q4 2024 | $4.2B | -5.1% |
TEVA's revenue is shrinking: $4.4B last quarter, down 1.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -3.4 points |
| Q2 2026 | -5.6% | -17 points |
| Q1 2026 | 16% | +3 points |
| Q4 2025 | 20% | +21 points |
| Q3 2025 | 20% | +21 points |
| Q2 2025 | 11% | +11 points |
| Q1 2025 | 13% | +19 points |
| Q4 2024 | -0.7% | -17 points |
TEVA's operating margin was 16% last quarter, down 3.4 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TEVA on cash flow, with more consistent year-over-year improvement.
TEVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $121M | -48% |
| Q2 2026 | $307M | +134% |
| Q1 2026 | -$208M | +$24M |
| Q4 2025 | $1B | +128% |
| Q3 2025 | $233M | -57% |
| Q2 2025 | $131M | +2083% |
| Q1 2025 | -$232M | +$16M |
| Q4 2024 | $446M | -58% |
TEVA generated $1.2B in free cash flow over the past year, up 114% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TEVA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TEVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +18M shares |
| 1 year | +1.6% | +19M shares |
| 3 years | +4.2% | +48M shares |
| 5 years | +6.7% | +74M shares |
| Available history | +8.4% | +92M shares |
TEVA has 1.2B diluted shares, up 1.6% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over TEVA on leverage, with a lower net debt burden relative to earnings.
TEVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.9x | High |
| Q2 2026 | 6.8x | High |
| Q1 2026 | 4.7x | High |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 5.2x | High |
| Q2 2025 | 8.1x | High |
| Q1 2025 | 10.5x | High |
| Q4 2024 | 21.6x | High |
TEVA's net debt is about 6.9 years of its operating earnings (EBITDA), up from 5.2 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TEVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.1 | Overbought |
| Stochastic | 93.7 | Overbought |
TEVA's weekly RSI is 70 (overbought) and its Stochastic is 94 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over TEVA on valuation relative to its sector.
TEVA PE vs Healthcare Sector
| Metric | TEVA | Sector median | Relative |
|---|---|---|---|
| PE | 99x | 26x | 284% above |
| PE % | 100 | 29 | 71 pts above |
TEVA is trading at 99x earnings, a 284% premium to the Healthcare sector's median of 26x.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
TEVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $41.1 | 6.1% above |
| 20 week MA | $37.6 | 16% above |
| 50 week MA | $34.4 | 27% above |
| 100 week MA | $26.3 | 66% above |
| 200 week MA | $19.4 | 125% above |
TEVA is in an uptrend: it's above all five of its weekly moving averages, and 125% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
TEVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.96 | $9.83 | -1.3% |
| 2021 | $9.83 | $8.46 | -14% |
| 2022 | $8.46 | $9.24 | +9.2% |
| 2023 | $9.24 | $10.4 | +13% |
| 2024 | $10.4 | $22.8 | +118% |
| 2025 | $22.8 | $31.9 | +40% |
| 2026 YTD | $31.9 | $43.7 | +37% |
TEVA has the edge over LLY on returns for 2026, with the stronger performance.